Role of abbreviated radiotherapy schedule in treatment of post-operative cervical and endometrial cancer

Phase 2

• Conditions: Health Condition 1: C530- Malignant neoplasm of endocervixHealth Condition 2: C53- Malignant neoplasm of cervix uteriHealth Condition 3: D- Radiation Therapy

• Registration Number: CTRI/2023/02/050123
• Lead Sponsor: Tata Memorial Centre Research Administrative Council

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Eastern Cooperative Oncology Group (ECOG) performance status of =2

2.Carcinoma of the cervix post-surgery with intermediate or high-risk features or needing adjuvant RT ± concurrent chemotherapy OR Carcinoma of the endometrium post-surgery requiring adjuvant (chemo)radiotherapy to pelvis with/without vaginal brachytherapy.

Exclusion Criteria

1. Patients with macroscopic residual disease (R+ resection) post operatively

2. Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer)

3. Patients treated with chemotherapy for any prior malignancy at any time

4. Patients treated with pelvic radiation previously

5. Patients with human immunodeficiency virus infection

6. Any preexisting medical conditions that may interfere with assessment of GU or GI toxicity

(This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemarrhoids precluding analysis of gastro-intestinal toxicities, and urinary incontinence, recurrent urinary tract infections)

Study & Design

• Study Type: Interventional
• Study Design: Not specified